Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | MEP1B | Q16820 | 2/20 | 0.54 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.51 |
| ▸ | ANPEP | P15144 | 1/20 | 0.51 |
| ▸ | MMP2 | P08253 | 1/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11581853 | 1.00 | MME (0.56) | MMEALDH1A1NPSR1MEP1BPSMB5 | |
| SCHEMBL73955 | 1.00 | MME (0.56) | MMEALDH1A1NPSR1MEP1BPSMB5 | |
| Hydrochloric Acid SCHEMBL1027766 | 0.98 | MME (0.54) | MMEALDH1A1NPSR1MEP1BPSMB5 | |
| Hydrochloric Acid SCHEMBL7362927 | 0.98 | MME (0.54) | MMEALDH1A1NPSR1MEP1BPSMB5 | |
| SCHEMBL17915462 | 0.93 | MME (0.61) | MMEALDH1A1MMP2MMP9 | |
| SCHEMBL121370 | 0.92 | MME (0.58) | MMEALDH1A1PSMB5NAALAD2FOLH1 | |
| SCHEMBL121371 | 0.92 | MME (0.58) | MMEALDH1A1PSMB5NAALAD2FOLH1 | |
| Benzophenone SCHEMBL9490253 | 0.92 | MEP1B (0.55) | MMEALDH1A1NPSR1MEP1BPSMB5 | |
| SCHEMBL11346818 | 0.92 | MME (0.58) | MMEALDH1A1PSMB5NAALAD2FOLH1 | |
| Benzophenone SCHEMBL9490249 | 0.92 | MEP1B (0.55) | MMEALDH1A1NPSR1MEP1BPSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 639 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118239879-A | Method for preparing 3-substituted oxindole, dihydroisoindigo and tetra-substituted ethane based on primary amine and application of primary amine | 泰山学院 | 2024-06-25 | — | — | CN | claimed |
| EP-1144384-B1 | COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARM INC (US) | 2007-10-31 | — | — | EP | claimed |
| US-12594342-B2 | Method of conjugation of Cys-mAbs | AMGEN INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-20260077054-A1 | COMBINATIONS OF ANTI-GIP ANTIBODIES AND INCRETINS AND USES THEREOF | HELICORE BIOPHARMA INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260034235-A1 | METHOD OF CONJUGATION OF CYS-MABS | AMGEN INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260001956-A1 | METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING BINDING PROTEINS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR) IN COMBINATION WITH GLP-1 AGONISTS | AMGEN INC. (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250376529-A1 | METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING BINDING PROTEINS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR) IN COMBINATION WITH GLP-1 AGONISTS | AMGEN INC. (US) | 2025-12-11 | — | — | US | disclosed |
| US-12465652-B2 | Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (GIPR)/GLP-1 receptor agonist fusion proteins | AMGEN INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250319196-A1 | METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING ANTAGONISTIC BINDING PROTEINS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR)/GLP-1 RECEPTOR AGONIST FUSION PROTEINS | AMGEN INC. (US) | 2025-10-16 | — | — | US | disclosed |
| US-12435149-B2 | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists | AMGEN INC. (US) | 2025-10-07 | — | — | US | disclosed |
| EP-4615875-A1 | METHODS FOR TREATING OBESITY | AMGEN INC. (US) | 2025-09-17 | — | — | EP | disclosed |
| WO-1996025394-A1 | Nα-2-(4-NITROPHENULSULFONYL)ETHOXYCARBONYL-AMINO ACIDS | HYUNDAI PHARM. IND. CO., LTD. (KR) | 1996-08-22 | — | — | WO | disclosed |
| WO-1996023801-A2 | NOVEL COMPOUNDS AND METHODS FOR MAKING AND USING SAME | GILEAD SCIENCES, INC. (US) | 1996-08-08 | — | — | WO | disclosed |
| EP-0719274-A1 | METHOD FOR DOSING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 1996-07-03 | — | — | EP | disclosed |
| EP-0719273-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1996-07-03 | — | — | EP | disclosed |
| WO-1995007919-A1 | METHOD FOR DOSING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 1995-03-23 | — | — | WO | disclosed |
| WO-1995007920-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1995-03-23 | — | — | WO | disclosed |
| EP-0107860-B1 | PEPTIDES, PROCESS FOR PREPARING THE SAME AND PSYCHODEPRESSANT COMPOSITIONS CONTAINING THE SAME | AMANO PHARMACEUTICAL CO., LTD. (JP) | 1986-09-17 | — | — | EP | disclosed |
| EP-0107860-A1 | Peptides, process for preparing the same and psychodepressant compositions containing the same | AMANO PHARMACEUTICAL CO., LTD. (JP) | 1984-05-09 | — | — | EP | disclosed |
| US-4069385-A | FROM AN OLEFIN AND AN ORGANIC PEROXIDE WITH COPPER-SCHIFF BASE COMPEX AS CATALYST | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1978-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12594342-B2 | Method of conjugation of Cys-mAbs | TST, PTMS, TMT1A | MME 4274/4885ALDH1A1 2691/4885NPSR1 3287/4885 |
| US-20260034235-A1 | METHOD OF CONJUGATION OF CYS-MABS | CBS, GCLC, PTMS | MME 2491/4885ALDH1A1 3399/4885NPSR1 2657/4885 |
| US-20260001956-A1 | METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING BINDING PROTEINS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR) IN COMBINATION WITH GLP-1 AGONISTS | GIPR, GLP1R, IAPP | MME 1609/4885ALDH1A1 4129/4885NPSR1 470/4885 |
| US-20260077054-A1 | COMBINATIONS OF ANTI-GIP ANTIBODIES AND INCRETINS AND USES THEREOF | GIPR, GLP1R, GPR119 | MME 1884/4885ALDH1A1 4411/4885NPSR1 937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.